Welcome to our dedicated page for Immunovant SEC filings (Ticker: IMVT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Immunovant, Inc. filings document the formal disclosures of a clinical-stage immunology company developing anti-FcRn product candidates for autoimmune diseases. Recent Form 8-K reports cover quarterly financial results, operating updates, research and development activity, clinical program communications for Graves’ disease and related indications, financing disclosure and other material events.
Proxy and governance filings describe annual meeting matters, director elections, auditor ratification, executive compensation, equity awards and stockholder voting results. Officer-transition and compensation-related 8-Ks add detail on employment agreements, severance arrangements, consulting services and incentive awards, while the company’s disclosures frame capital structure and governance around its single development-focused operating segment.
Immunovant, Inc. Chief Technology Officer Jay S. Stout reported selling a total of 10,132 shares of common stock on April 8, 2026, at a weighted average price of $24.83 per share. According to the footnotes, these sales were mandated "sell to cover" transactions to satisfy tax withholding obligations tied to the vesting of previously granted restricted stock units.
The filing states that part of the sale related to 19,045 RSUs that vested on April 1, 2026, from a 76,181-RSU grant made on April 1, 2025, and part related to 3,436 RSUs that vested on April 2, 2026, from a 54,978-RSU grant made on April 2, 2024. After these transactions, Stout directly holds 254,439 shares of Immunovant common stock.
Immunovant, Inc. director Frank Torti reported equity awards consisting of stock options and restricted stock units as part of his compensation. He received options for 88,325 shares of common stock at an exercise price of $24.61 per share, expiring in 2036. He was also granted 174,189 restricted stock units (RSUs), each representing one share of common stock upon vesting. Both the options and RSUs vest in substantially equal quarterly installments over two years starting from April 1, 2026, contingent on his continuous service. Following the common stock award, he directly holds 1,009,228 shares of Immunovant common stock.
Immunovant, Inc. director Andrew J. Fromkin received equity compensation on April 7, 2026. He was granted 13,880 restricted stock units under the 2019 Equity Incentive Plan, with each RSU representing one share of common stock upon vesting.
He was also granted stock options for 7,061 shares of common stock at an exercise price of $24.61 per share, expiring April 7, 2036. Both the RSUs and options vest in full on April 1, 2027, subject to his continuous service. Following the RSU grant, he holds 99,732 shares of common stock directly, and the RSUs may be settled later if he elects deferral under Rule 409A.
Immunovant, Inc. reported that director Douglas J. Hughes received new equity awards as part of his compensation. He was granted 13,880 shares of Common Stock in the form of restricted stock units, bringing his direct holdings to 134,653 common shares after the grant.
He also received a stock option covering 7,061 shares of Common Stock at an exercise price of $24.61 per share. Both the RSUs and the option awards vest in full on April 1, 2027, subject to his continuous service with the company, and the options expire on April 7, 2036. The RSUs may be settled later at his election, subject to Rule 409A.
Immunovant, Inc. director Atul Pande received new equity awards as part of his compensation. He was granted stock options for 7,061 shares of common stock at an exercise price of $24.61 per share, expiring on April 7, 2036. He also received 13,880 shares of common stock in the form of restricted stock units. These RSUs and the option shares will vest on April 1, 2027, if he continues service with the company through that date. Following these awards, he holds 116,731 common shares directly and 20,000 common shares indirectly through a trust.
Immunovant, Inc. director Jake Bauer reported receiving new equity awards as part of his compensation. On April 7, 2026 he was granted 13,880 shares of Common Stock in the form of restricted stock units under the company’s 2019 Equity Incentive Plan. These RSUs vest in full on April 1, 2027, conditional on his continuous service, and each unit converts into one share, with an option to defer settlement under Rule 409A. He also received a stock option for 7,061 shares at an exercise price of $24.61 per share, expiring April 7, 2036, which will vest on April 1, 2027 on the same service condition. Following the stock grant, he directly owns 38,896 shares of Immunovant common stock.
Immunovant, Inc. director Robert Graham Susman reported equity awards consisting of new stock options and restricted stock units (RSUs). He was granted options for 7,061 shares of common stock at an exercise price of $24.61 per share, expiring on April 7, 2036. The shares underlying these options will vest on April 1, 2027, subject to his continuous service. He also received 13,880 RSUs, each representing one share of common stock, which will vest in full on April 1, 2027 under the same service condition. The filing notes he may elect to defer settlement of the RSUs upon vesting, subject to the requirements of Rule 409A. Following the RSU grant, he directly owns 38,896 shares of common stock.
Gloria Melanie reported acquisition or exercise transactions in this Form 4 filing.
Immunovant, Inc. Chief Operating Officer Gloria Melanie received new equity awards. On April 7, 2026 she was granted options to buy 121,063 shares of common stock at $24.61 per share, expiring on April 7, 2036, and 83,671 restricted stock units at no cost.
The RSUs vest 25% on April 1, 2027, with the remainder vesting in twelve substantially equal quarterly installments after that date, subject to continued service. The options vest 25% on April 1, 2027, with the balance vesting in thirty-six substantially equal monthly installments, also conditioned on continued service. After these grants, she directly owns 253,944 common shares.
Immunovant, Inc. Chief Technology Officer Jay S. Stout received new equity awards as compensation. He was granted stock options for 96,851 shares of common stock at an exercise price of $24.61 per share, expiring on April 7, 2036, and 66,937 restricted stock units (RSUs).
The RSUs vest as to 25% of the shares on April 1, 2027, with the remaining 75% vesting in twelve successive substantially equal quarterly installments, contingent on continued service. The options vest as to 25% on April 1, 2027, with the balance vesting in thirty-six successive substantially equal monthly installments, also subject to continued service. Following these grants, he directly owns 264,571 shares of common stock.
Immunovant, Inc. granted Chief Legal Officer Christopher Van Tuyl equity awards on April 7, 2026. He received stock options for 59,820 shares of common stock at an exercise price of $24.61 per share, expiring on April 7, 2036.
He was also granted 41,343 restricted stock units (RSUs), each representing one share of common stock. Both the RSUs and the option shares vest as to 25% on April 1, 2027, with the remaining amounts vesting in regular installments thereafter, contingent on his continued service. Following the grant, he directly holds 188,396 shares of common stock.